詳細検索

詳細検索

×

キーワード検索の使い方

×
A
B
C
D
E
F
G
H
I
J
L
M
N
O
P
Q
R
S
T
U
V
W
X
日

お問い合わせ

世界の病理組織用ミクロトーム市場の展望、詳細分析、および2032年までの予測

世界の病理組織用ミクロトーム市場の展望、詳細分析、および2032年までの予測


Global Pathological Tissue Microtome Market Outlook, InDepth Analysis & Forecast to 2032

世界の病理組織用ミクロトーム市場は、主要な製品セグメントと多様な用途に牽引され、2025年の2億2,800万米ドルから2032年には2億9,100万米ドルへと、年平均成長率（CAGR）3.6%（2026～2032年）で成長すると予... もっと見る

　

　

出版社
QYResearch
QYリサーチ
出版年月
2026年9月24日
電子版価格
US$4,900
シングルユーザライセンス
ライセンス・価格情報／注文方法はこちら
納期
5-7営業日
言語
英語

英語原文をAIを使って翻訳しています。


　

サマリー

世界の病理組織用ミクロトーム市場は、主要な製品セグメントと多様な用途に牽引され、2025年の2億2,800万米ドルから2032年には2億9,100万米ドルへと、年平均成長率（CAGR）3.6%（2026～2032年）で成長すると予測されています。
病理組織用ミクロトームは、主に疾患診断を目的とした顕微鏡検査のために、生体組織を極めて薄くスライス（切片化）する医療検査室向けの精密機器です。細胞の異常、腫瘍、その他の病理学的変化を特定する上で、正確かつ均一な組織切片の作製が不可欠となる組織病理学において、本装置は重要な役割を果たします。ミクロトームを使用することで、検査技師はパラフィン包埋または凍結処理されたサンプルから、数ミクロン単位の厚さの切片を作製することができます。作製された切片は染色され、顕微鏡下で分析されます。病理組織用ミクロトームには、ロータリー式、スライディング式、クライオスタット、ウルトラミクロトームなど様々な種類があり、それぞれが特定のサンプルタイプや診断要件に適しています。
主な調査結果
2025年における病理用ミクロトームの世界販売台数は35,000台に達すると予測されています。生産能力は約50,000台、平均販売価格は1台あたり6,500米ドル、平均粗利益率は50%～60%となる見込みです。
出荷台数ベースでは、パラフィン用ミクロトームが最大の製品セグメントとなりました。
世界的に、病理診断が依然として主要な用途市場となっています。
市場動向
病理組織用ミクロトーム市場は、高精度化、自動化、およびデジタル病理システムとの統合へと向かっています。従来の組織切片作製ワークフローは、半自動化・自動化技術の導入により高度化が進んでおり、これにより切片の均一性の向上、作業者への依存度の低減、検査室の生産性向上が図られています。病理検査室においてデジタル画像処理、AI支援診断、標準化されたワークフローの採用が進むにつれ、精度、再現性、ワークフローへの適合性に優れた組織切片作製システムへの需要が高まっています。さらに、精密医療（プレシジョン・メディシン）、分子病理学、生物医学研究、医薬品開発といった分野での用途拡大に伴い、多様な組織調製要件に対応可能な、より専門性の高いシステムの開発がメーカー各社によって進められています。

産業チェーンの分析
病理組織用ミクロトームの産業チェーンは、上流の精密部品サプライヤー、中流の機器メーカー、そして下流の医療・研究・製薬分野のユーザーで構成されています。上流のサプライヤーは、精密機械部品、切削用ブレード、モーター、制御システム、温度制御モジュール、構造用材料などを供給します。中流のメーカーは、これらの部品を統合し、サンプル位置決め、厚さ調整、切削制御、運用管理機能を備えた組織切片作製システムを製造します。
主な付加価値創出領域は、機械的精度、切片作製の安定性、自動化機能、および病理ワークフローとの適合性にあります。一般的な実験機器と比較して、病理組織用ミクロトームは、専用の消耗品、保守サービス、アクセサリー、そしてデジタル病理プラットフォームとの統合を通じて、さらなる付加価値を生み出しています。下流のユーザーには、主に病院、病理検査室、医療検査センター、大学、研究機関、製薬会社などが含まれます。
セグメント別の考察
病理組織用ミクロトーム市場は、切片作製技術、自動化レベル、サンプル調製方法、および用途分野によって区分できます。パラフィン包埋用ミクロトームは、日常的な病理組織診断で広く使用されているため、出荷台数ベースで最大のセグメントを占めています。一方、クライオスタット（凍結ミクロトーム）は、術中迅速診断や凍結組織解析の需要に支えられた、専門性が高く付加価値の大きいセグメントとなっています。
自動化の観点からは、手動および半自動システムが、臨床現場での実績が豊富であることやコスト面での利点から、現在、導入済み機器の大部分を占めています。完全自動化された組織切片作製システムは、特に標準化された運用や検査室の効率化が求められる大規模な病理センターにおいて、より付加価値の高い開発の方向性を示しています。また、振動式や超薄切片作製技術を含む研究用システムは、専門的な生物医学分野において新たな機会を提供しています。

下流市場における機会
病理組織用ミクロトームは、主に標準化された組織サンプル調製を必要とする医療診断、生物医学研究、および医薬品開発の現場で使用されています。病院や病理検査室では、腫瘍診断、生検検査、組織形態解析、日常的な病理組織検査などにこれらのシステムが利用されています。研究機関では細胞生物学、神経科学、組織構造の研究に、製薬企業では薬剤評価や毒性学研究に活用されています。今後は、診断需要の増加、デジタル病理の拡大、精密医療（プレシジョン・メディシン）の継続的な発展に伴い、新たな市場機会が創出されると見込まれています。
地域別の動向
北米は、高度な医療インフラ、確立された病理検査体制、そしてデジタル病理技術の高い導入率を背景に、病理組織用ミクロトームの主要市場の一つとなっています。同地域の病院、診断センター、研究機関からは、高性能な組織切片作製装置に対する安定した需要があります。
欧州もまた、成熟した医学研究能力、高度な病理サービス、活発な医薬品開発活動に支えられ、重要な市場的地位を占めています。アジア太平洋地域は、医療インフラの拡充、診断能力の向上、生物医学研究への投資拡大を牽引役として、成長著しい主要地域となりつつあります。地域間の差異は、主に検査室の近代化レベル、医療への投資状況、および高度な病理技術の導入状況に表れています。
競争環境の分析
病理組織用ミクロトーム市場は、病理検査機器の専門メーカーと、より広範なライフサイエンス機器を取り扱う企業との間の競争によって特徴づけられます。競争優位性は、主に切片作製の精度、装置の信頼性、自動化機能、製品ポートフォリオ、臨床応用における実績、そしてグローバルなサービスネットワークに依存しています。包括的な病理ワークフロー・ソリューションを提供する企業は、病院や診断検査室の市場において優位性を確保している一方、専門メーカーは研究や高度なサンプル調製分野で競争力を維持しています。市場は徐々に、統合型病理ソリューション、高度な自動化、切片作製の均一性向上、そしてデジタル病理エコシステムとの親和性強化へと進化を遂げています。

レポートの範囲
本レポートは、バリューチェーン全体にわたる生産および販売実績を統合し、世界の病理組織用ミクロトーム市場を包括的（360度）な視点で捉えることで、ビジネスリーダー、意思決定者、ステークホルダーに有益な情報を提供します。過去の販売数量および売上データ（2021年～2025年）を分析し、2032年までの予測を提示するとともに、需要動向や成長の原動力を明らかにします。
市場を「タイプ」および「用途」別に区分し、数量・金額、成長率、技術革新、ニッチな市場機会、代替リスクを定量化・分析するほか、川下顧客の分布パターンについても考察します。
地域別の詳細な分析では、5つの主要市場（北米、欧州、APAC、南米、MEA）を網羅し、20カ国以上について掘り下げた分析を行っています。各地域における主要製品、競争環境、川下の需要動向が詳細に示されています。
重要な競争情報として、主要メーカーのプロファイル（販売数量、売上高、利益率、価格戦略、主要顧客）を提示し、製品ライン、用途、地域ごとのトップ企業の立ち位置を分析して、その戦略的強みを明らかにします。
サプライチェーンの概要では、川上のサプライヤー、製造技術、コスト構造、流通動向を整理し、戦略的なギャップや未充足の需要を特定します。
市場セグメンテーション
企業別
Leica Biosystems
Sakura Finetek
Thermo Fisher Scientific
Medite
Slee Medical
RMC Boeckeler
MICROS Austria
AGD Biomedicals
Amos Scientific
Bright Instrument
Diapath
Histo-Line Laboratories
Auxilab
Nanolytik
Orion Medic
S.M. Scientific
RWD
Dakewe
YIDI Medical
タイプ別区分
回転式ミクロトーム
クリオスタット・ミクロトーム
スライド式ミクロトーム
その他
自動化レベル別区分
手動式ミクロトーム
半自動式ミクロトーム
全自動式ミクロトーム
切片厚別区分
1～10 μm
0.1～1 μm
20～100 nm
用途別区分
病理診断
医薬品
科学研究
その他
地域別売上
北米
米国
カナダ
メキシコ
アジア太平洋地域
中国
日本
韓国
インド
台湾
東南アジア（インドネシア、ベトナム、タイ）
欧州
ドイツ
フランス
英国
イタリア
ロシア
中南米
ブラジル
アルゼンチン
その他の中南米諸国
中東・アフリカ
トルコ
エジプト
GCC諸国
南アフリカ

章構成
第1章：病理組織用ミクロトーム市場の調査範囲を定義し、タイプや用途別に市場を区分。各セグメントの規模と成長の可能性を概説します。
第2章：市場の現状を提示し、2032年までの世界的な売上高と販売量を予測。主要な消費地域や新興市場における成長の起爆剤を特定します。
第3章：メーカーの状況を詳細に分析：販売量と売上高によるランキング、収益性と価格設定の分析、生産拠点の分布、製品タイプ別の業績詳細、市場集中度およびM&A動向の評価を行います。
第4章：高利益率の製品セグメントを特定：販売量、売上高、平均販売価格（ASP）、技術的差別化要因を比較し、成長が見込まれるニッチ分野や代替品への移行リスクを明らかにします。
第5章：下流市場の機会を分析：用途別の販売量・売上高・価格を評価し、新たな用途を特定。地域および用途別の主要顧客プロファイルを提示します。
第6章：北米：用途および国別の販売量・売上高の内訳、主要メーカーのプロファイル、成長要因と阻害要因の評価を行います。
第7章：欧州：用途およびメーカー別の地域市場（販売量・売上高）を分析し、成長要因と阻害要因を提示します。
第8章：アジア太平洋地域：用途および地域・国別の販売量・売上高を定量化し、主要メーカーのプロファイルと、拡大の可能性が高い分野を明らかにします。
第9章：中南米：用途および国別の販売量・売上高を測定し、主要メーカーのプロファイルと、投資機会および課題を特定します。
第10章：中東・アフリカ：用途および国別の販売量・売上高を評価し、主要メーカーのプロファイルと、投資の見通しおよび市場参入の障壁を概説します。
第11章：メーカーの詳細プロファイル：製品仕様、販売量、売上高、利益率を詳述。主要メーカーについて、2025年の製品タイプ・用途・販売地域別の売上内訳、SWOT分析、最近の戦略的動向をまとめます。
第12章：サプライチェーン：上流の原材料・サプライヤー、生産体制、地域別の生産・コスト、規制・技術動向を分析し、下流の流通チャネルや販売代理店の役割についても検討します。
第13章：市場動向：成長要因、阻害要因、規制の影響、リスク軽減策を探ります。
第14章：実践的な結論と戦略的提言。本レポートの意義
単なる市場データの枠を超え、本分析は収益性向上のための明確な指針を提示し、以下の取り組みを可能にします。
高成長地域（第6～10章）や高利益セグメント（第5章）への戦略的な資本配分。
コストや需要に関する知見を武器に、サプライヤー（第12章）や顧客（第5章）と優位な立場で交渉。
競合他社の事業運営、利益率、戦略に関する詳細な分析に基づき、競争で優位に立つ（第3章および第11章）。
サプライチェーンの上流から下流までを可視化し、混乱に強い体制を構築する（第12章および第13章）。
こうした包括的な情報を活用し、市場の複雑さを、実行可能な競争優位性へと転換する。



お問い合わせ

お問合せ種類／内容 *

補足が有ればご記入ください
貴社名*
ご担当者名 * 姓 名
メールアドレス *

ページTOPに戻る


目次

1 調査範囲
1.1 病理組織用ミクロトームの概要：定義、特性、および主な特徴
1.2 タイプ別市場区分
1.2.1 タイプ別世界病理組織用ミクロトーム市場規模（2021年、2025年、2032年）
1.2.2 ロータリー式ミクロトーム
1.2.3 クライオスタット・ミクロトーム
1.2.4 スライディング式ミクロトーム
1.2.5 その他
1.3 自動化レベル別市場区分
1.3.1 自動化レベル別世界病理組織用ミクロトーム市場規模（2021年、2025年、2032年）
1.3.2 手動式ミクロトーム
1.3.3 半自動式ミクロトーム
1.3.4 全自動式ミクロトーム
1.4 切片厚別市場区分
1.4.1 切片厚別世界病理組織用ミクロトーム市場規模（2021年、2025年、2032年）
1.4.2 1～10 μm
1.4.3 0.1～1 μm
1.4.4 20～100 nm
1.5 用途別市場区分
1.5.1 用途別世界病理組織用ミクロトーム市場規模（2021年、2025年、2032年）
1.5.2 病理診断
1.5.3 医薬品
1.5.4 科学研究
1.5.5 その他
1.6 前提条件と制約事項
1.7 調査の目的
1.8 対象期間

2 エグゼクティブ・サマリー
2.1 世界の病理組織用ミクロトーム市場の売上高推計および予測（2021～2032年）
2.2 地域別世界病理組織用ミクロトーム市場売上高
2.2.1 売上高比較：2021年 vs 2025年 vs 2032年
2.2.2 地域別売上高の推移と予測 (2021-2032年)
2.2.3 地域別世界売上高シェア (2021-2032年)
2.3 病理組織用ミクロトームの世界販売台数推計と予測 (2021-2032年)
2.4 地域別病理組織用ミクロトーム販売台数
2.4.1 販売台数比較：2021年 vs 2025年 vs 2032年
2.4.2 地域別販売台数の推移と予測 (2021-2032年)
2.4.3 新興市場の焦点：成長要因と投資動向
2.4.4 地域別世界販売台数シェア (2021-2032年)

3 競争環境
3.1 メーカー別病理組織用ミクロトーム販売台数
3.1.1 メーカー別世界販売台数 (2021-2026年)
3.1.2 販売台数ベースの世界トップ5およびトップ10メーカーのシェア (2025年)
3.2 病理組織用ミクロトームメーカーの売上高ランキングと階層区分
3.2.1 メーカー別世界売上高 (2021-2026年)
3.2.2 主要メーカーの世界売上高ランキング (2024年 vs 2025年)
3.2.3 売上高に基づく階層区分 (Tier 1、Tier 2、Tier 3)
3.3 メーカーの収益性プロファイルと価格戦略
3.3.1 主要メーカーの売上総利益率 (2021年 vs 2025年)
3.3.2 メーカー別価格動向 (2021-2026年)
3.4 主要メーカーの製造拠点と本社所在地
3.5 製品タイプ別主要メーカーシェア
3.5.1 ロータリー式ミクロトーム：主要メーカー別シェア主要メーカー
3.5.2 クリヨスタット・ミクロトーム：主要メーカー別市場シェア
3.5.3 スライディング・ミクロトーム：主要メーカー別市場シェア
3.5.4 その他：主要メーカー別市場シェア
3.6 世界の病理組織用ミクロトーム市場の集中度と動向
3.6.1 世界市場の集中度
3.6.2 市場参入・退出の影響分析
3.6.3 戦略的動向：M&A、生産能力の拡大、R&D投資

4 製品セグメンテーション
4.1 タイプ別：世界の病理組織用ミクロトーム販売実績
4.1.1 タイプ別：世界の病理組織用ミクロトーム販売台数 (2021-2032年)
4.1.2 タイプ別：世界の病理組織用ミクロトーム売上高 (2021-2032年)
4.1.3 タイプ別：世界の平均販売価格（ASP）の推移 (2021-2032年)
4.2 自動化レベル別：世界の病理組織用ミクロトーム販売実績
4.2.1 自動化レベル別：世界の病理組織用ミクロトーム販売台数 (2021-2032年)
4.2.2 自動化レベル別：世界の病理組織用ミクロトーム売上高 (2021-2032年)
4.2.3 自動化レベル別：世界の平均販売価格（ASP）の推移 (2021-2032年)
4.3 切片厚別：世界の病理組織用ミクロトーム販売実績
4.3.1 切片厚別：世界の病理組織用ミクロトーム販売台数 (2021-2032年)
4.3.2 切片厚別：世界の病理組織用ミクロトーム売上高 (2021-2032年)
4.3.3 切片厚別：世界の平均販売価格（ASP）の推移 (2021-2032年)
4.4 製品技術の差別化
4.5 サブタイプ別の動向：成長を牽引する分野、収益性、およびリスク
4.5.1 高成長ニッチ市場と導入促進要因
4.5.2 収益性の高い分野とコスト変動要因
4.5.3 代替技術による脅威

5 下流の用途および顧客
5.1 用途別：世界の病理組織用ミクロトーム販売
5.1.1 用途別：世界の販売実績および予測 (2021-2032年)
5.1.2 用途別：世界の販売市場シェア(2021-2032)
5.1.3 高成長が見込まれる用途の特定
5.1.4 新興の用途に関する事例研究
5.2 用途別：世界の病理組織用ミクロトームの売上高
5.2.1 用途別：世界の売上高の推移と予測 (2021-2032)
5.2.2 用途別：売上高ベースの市場シェア (2021-2032)
5.3 用途別：世界の価格動向 (2021-2032)
5.4 下流顧客の分析
5.4.1 地域別主要顧客
5.4.2 用途別主要顧客

6 北米
6.1 北米の販売数量および売上高 (2021-2032)
6.2 2025年における北米の主要メーカーの売上高
6.3 北米の病理組織用ミクロトーム：用途別販売数量および売上高 (2021-2032)
6.4 北米市場における成長促進要因と市場参入障壁
6.5 国別：北米の病理組織用ミクロトーム市場規模
6.5.1 国別：北米の売上高
6.5.2 国別：北米の販売動向
6.5.3 米国
6.5.4 カナダ
6.5.5 メキシコ

7 欧州
7.1 欧州の販売数量および売上高 (2021-2032年)
7.2 2025年における欧州の主要メーカーの売上高
7.3 用途別：欧州の病理組織用ミクロトームの販売数量および売上高 (2021-2032年)
7.4 欧州市場における成長促進要因と市場障壁
7.5 国別：欧州の病理組織用ミクロトーム市場規模
7.5.1 国別：欧州の売上高
7.5.2 国別：欧州の販売動向
7.5.3 ドイツ
7.5.4 フランス
7.5.5 英国
7.5.6 イタリア
7.5.7 ロシア

8 アジア太平洋地域
8.1 アジア太平洋地域の販売数量および売上高 (2021-2032年)
8.2 2025年におけるアジア太平洋地域の主要メーカーの売上高
8.3 用途別：アジア太平洋地域の病理組織用ミクロトームの販売数量および売上高 (2021-2032年)
8.4 地域別：アジア太平洋地域の病理組織用ミクロトーム市場規模
8.4.1 地域別：アジア太平洋地域の売上高
8.4.2 地域別：アジア太平洋地域の販売動向
8.5 アジア太平洋地域における成長促進要因と市場障壁
8.6 東南アジア
8.6.1 国別：東南アジアの売上高 (2021年 vs 2025年 vs 2032年)
8.6.2 主要国分析：インドネシア、ベトナム、タイ、マレーシア、フィリピン
8.7 中国
8.8 日本
8.9 韓国
8.10 台湾
8.11 インド

9 中南米
9.1 中南米の販売数量および売上高 (2021-2032年)
9.2 2025年における中南米の主要メーカーの売上高
9.3 用途別：中南米の病理組織用ミクロトームの販売数量および売上高(2021-2032年)
9.4 中南米における投資機会と主な課題
9.5 国別・中南米の病理組織用ミクロトーム市場規模
9.5.1 国別・中南米の売上高推移 (2021年 vs 2025年 vs 2032年)
9.5.2 ブラジル
9.5.3 アルゼンチン

10 中東・アフリカ
10.1 中東・アフリカの販売数量および売上高 (2021-2032年)
10.2 2025年における中東・アフリカの主要メーカー別売上高
10.3 用途別・中東・アフリカの病理組織用ミクロトーム販売数量および売上高 (2021-2032年)
10.4 中東・アフリカにおける投資機会と主な課題
10.5 国別・中東・アフリカの病理組織用ミクロトーム市場規模
10.5.1 国別・中東・アフリカの売上高推移 (2021年 vs 2025年 vs 2032年)
10.5.2 GCC諸国
10.5.3 トルコ
10.5.4 エジプト
10.5.5 南アフリカ

11 企業概要
11.1 Leica Biosystems
11.1.1 Leica Biosystems 企業情報
11.1.2 Leica Biosystems 事業概要
11.1.3 Leica Biosystems 病理組織用ミクロトームの製品モデル、概要、仕様
11.1.4 Leica Biosystems 病理組織用ミクロトームの販売台数、価格、売上高、粗利益率（2021-2026年）
11.1.5 Leica Biosystems 病理組織用ミクロトームの製品別販売台数（2025年）
11.1.6 Leica Biosystems 病理組織用ミクロトームの用途別販売台数（2025年）
11.1.7 Leica Biosystems 病理組織用ミクロトームの地域別販売台数（2025年）
11.1.8 Leica Biosystems 病理組織用ミクロトームのSWOT分析
11.1.9 Leica Biosystems 最近の動向
11.2 Sakura Finetek
11.2.1 Sakura Finetek 企業情報
11.2.2 Sakura Finetek 事業概要
11.2.3 Sakura Finetek 病理組織用ミクロトームの製品モデル、概要、仕様
11.2.4 Sakura Finetek 病理組織用ミクロトームの販売台数、価格、売上高、粗利益率（2021-2026年）
11.2.5 Sakura Finetek 病理組織用ミクロトームの製品別販売台数（2025年）
11.2.6 Sakura Finetek 病理組織用ミクロトームの用途別販売台数（2025年）
11.2.7 Sakura Finetek 病理組織用ミクロトームの地域別販売台数（2025年）
11.2.8 Sakura Finetek 病理組織用ミクロトームのSWOT分析
11.2.9 Sakura Finetek 最近の動向
11.3 Thermo Fisher Scientific
11.3.1 Thermo Fisher Scientific 企業情報
11.3.2 Thermo Fisher Scientific 事業概要
11.3.3 Thermo Fisher Scientific病理組織用ミクロトームの製品モデル、概要、および仕様
11.3.4 Thermo Fisher Scientific：病理組織用ミクロトームの販売台数、価格、売上高、および粗利益（2021-2026年）
11.3.5 Thermo Fisher Scientific：製品別病理組織用ミクロトーム販売台数（2025年）
11.3.6 Thermo Fisher Scientific：用途別病理組織用ミクロトーム販売台数（2025年）
11.3.7 Thermo Fisher Scientific：地域別病理組織用ミクロトーム販売台数（2025年）
11.3.8 Thermo Fisher Scientific：病理組織用ミクロトームのSWOT分析
11.3.9 Thermo Fisher Scientific：最近の動向
11.4 Medite
11.4.1 Medite：企業情報
11.4.2 Medite：事業概要
11.4.3 Medite：病理組織用ミクロトームの製品モデル、概要、および仕様
11.4.4 Medite：病理組織用ミクロトームの販売台数、価格、売上高、および粗利益（2021-2026年）
11.4.5 Medite：製品別病理組織用ミクロトーム販売台数（2025年）
11.4.6 Medite：用途別病理組織用ミクロトーム販売台数（2025年）
11.4.7 Medite：地域別病理組織用ミクロトーム販売台数（2025年）
11.4.8 Medite：病理組織用ミクロトームのSWOT分析
11.4.9 Medite：最近の動向
11.5 Slee Medical
11.5.1 Slee Medical：企業情報
11.5.2 Slee Medical：事業概要
11.5.3 Slee Medical：病理組織用ミクロトームの製品モデル、概要、および仕様
11.5.4 Slee Medical：病理組織用ミクロトームの販売台数、価格、売上高、および粗利益（2021-2026年）
11.5.5 Slee Medical：病理組織用ミクロトーム製品別売上高（2025年）
11.5.6 Slee Medical社：用途別病理組織用ミクロトーム売上高（2025年）
11.5.7 Slee Medical社：地域別病理組織用ミクロトーム売上高（2025年）
11.5.8 Slee Medical社：病理組織用ミクロトームのSWOT分析
11.5.9 Slee Medical社：最近の動向
11.6 RMC Boeckeler
11.6.1 RMC Boeckeler社：企業情報
11.6.2 RMC Boeckeler社：事業概要
11.6.3 RMC Boeckeler社：病理組織用ミクロトームの製品モデル、概要、仕様
11.6.4 RMC Boeckeler社：病理組織用ミクロトームの販売台数、価格、売上高、粗利益率（2021-2026年）
11.6.5 RMC Boeckeler社：最近の動向
11.7 MICROS Austria
11.7.1 MICROS Austria社：企業情報
11.7.2 MICROS Austria社：事業概要
11.7.3 MICROS Austria社：病理組織用ミクロトームの製品モデル、概要、仕様
11.7.4 MICROS Austria社：病理組織用ミクロトームの販売台数、価格、売上高、粗利益率（2021-2026年）
11.7.5 MICROS Austria社：最近の動向
11.8 AGD Biomedicals
11.8.1 AGD Biomedicals社：企業情報
11.8.2 AGD Biomedicals社：事業概要
11.8.3 AGD Biomedicals社：病理組織用ミクロトームの製品モデル、概要、仕様
11.8.4 AGD Biomedicals社：病理組織用ミクロトームの販売台数、価格、売上高、粗利益率（2021-2026年）
11.8.5 AGD Biomedicals社：最近の動向
11.9 Amos Scientific
11.9.1 Amos Scientific社：企業情報
11.9.2 Amos Scientific社：事業概要
11.9.3 Amos Scientific社 病理組織用ミクロトームの製品モデル、概要、および仕様
11.9.4 Amos Scientific社 病理組織用ミクロトームの販売量、価格、売上高、および粗利益率（2021-2026年）
11.9.5 Amos Scientific社の最近の動向
11.10 Bright Instrument
11.10.1 Bright Instrument社の企業情報
11.10.2 Bright Instrument社の事業概要
11.10.3 Bright Instrument社 病理組織用ミクロトームの製品モデル、概要、および仕様
11.10.4 Bright Instrument社 病理組織用ミクロトームの販売量、価格、売上高、および粗利益（2021-2026年）
11.10.5 Bright Instrument社の最近の動向
11.11 Diapath
11.11.1 Diapath社の企業情報
11.11.2 Diapath社の事業概要
11.11.3 Diapath社 病理組織用ミクロトームの製品モデル、概要、および仕様
11.11.4 Diapath社 病理組織用ミクロトームの販売量、価格、売上高、および粗利益（2021-2026年）
11.11.5 Diapath社の最近の動向
11.12 Histo-Line Laboratories
11.12.1 Histo-Line Laboratories社の企業情報
11.12.2 Histo-Line Laboratories社の事業概要
11.12.3 Histo-Line Laboratories社 病理組織用ミクロトームの製品モデル、概要、および仕様
11.12.4 Histo-Line Laboratories社 病理組織用ミクロトームの販売量、価格、売上高、および粗利益（2021-2026年）
11.12.5 Histo-Line Laboratories社の最近の動向
11.13 Auxilab
11.13.1 Auxilab社の企業情報
11.13.2 Auxilab社の事業概要
11.13.3 Auxilab社 病理組織用ミクロトームの製品モデル、概要、および仕様
11.13.4 Auxilab社 病理組織用ミクロトームの販売量、価格、売上高、および粗利益（2021-2026年）
11.13.5 Auxilab社の最近の動向
11.14 Nanolytik
11.14.1 Nanolytik社の企業情報
11.14.2 Nanolytik社の事業概要
11.14.3 Nanolytik社 病理組織用ミクロトームの製品モデル、概要、および仕様
11.14.4 Nanolytik社 病理組織用ミクロトームの販売量、価格、売上高、および粗利益（2021-2026年）
11.14.5 Nanolytik社の最近の動向
11.15 Orion Medic
11.15.1 Orion Medic 企業情報
11.15.2 Orion Medic 事業概要
11.15.3 Orion Medic 病理組織用ミクロトームの製品モデル、概要、および仕様
11.15.4 Orion Medic 病理組織用ミクロトームの販売量、価格、売上高、および粗利益（2021-2026年）
11.15.5 Orion Medicの最近の動向
11.16 S.M. Scientific
11.16.1 S.M. Scientific 企業情報
11.16.2 S.M. Scientific 事業概要
11.16.3 S.M. Scientific 病理組織用ミクロトームの製品モデル、概要、および仕様
11.16.4 S.M. Scientific 病理組織用ミクロトームの販売量、価格、売上高、および粗利益（2021-2026年）
11.16.5 S.M. 11.17 RWD
11.17.1 RWD 企業情報
11.17.2 RWD 事業概要
11.17.3 RWD 病理組織用ミクロトームの製品モデル、概要、仕様
11.17.4 RWD 病理組織用ミクロトームの販売台数、価格、売上高、粗利益率 (2021-2026年)
11.17.5 RWD 最近の動向
11.18 Dakewe
11.18.1 Dakewe 企業情報
11.18.2 Dakewe 事業概要
11.18.3 Dakewe 病理組織用ミクロトームの製品モデル、概要、仕様
11.18.4 Dakewe 病理組織用ミクロトームの販売台数、価格、売上高、粗利益率 (2021-2026年)
11.18.5 Dakewe 最近の動向
11.19 YIDI Medical
11.19.1 YIDI Medical 企業情報
11.19.2 YIDI Medical 事業概要
11.19.3 YIDI Medical 病理組織用ミクロトームの製品モデル、概要、仕様
11.19.4 YIDI Medical 病理組織用ミクロトームの販売台数、価格、売上高、粗利益率 (2021-2026年)
11.19.5 YIDI Medical 最近の動向

12 バリューチェーンおよびサプライチェーン分析
12.1 病理組織用ミクロトームの産業チェーン
12.2 病理組織用ミクロトームの上流工程（原材料）分析
12.2.1 原材料
12.2.2 主要サプライヤーの市場シェアとリスク評価
12.3 病理組織用ミクロトームの生産体制分析
12.3.1 製造拠点（フットプリント）の分析
12.3.2 地域別生産市場シェア（2021-2032年）
12.3.3 規制および貿易政策が生産に及ぼす影響
12.3.4 生産技術の概要
12.3.5 地域別コスト要因
12.4 病理組織用ミクロトームの販売チャネルおよび流通ネットワーク
12.4.1 販売チャネル
12.4.2 販売代理店

13 病理組織用ミクロトーム市場の動向
13.1 業界のトレンドと変遷
13.2 市場成長の促進要因と新たな機会
13.3 市場の課題、リスク、および制約要因
13.4 米国の関税による影響

14 世界の病理組織用ミクロトーム市場調査における主要な知見

15 付録
15.1 調査手法
15.1.1 手法／調査アプローチ
15.1.1.1 調査プログラム／設計
15.1.1.2 市場規模の推定
15.1.1.3 市場の内訳とデータのクロスチェック（トライアンギュレーション）
15.1.2 データソース
15.1.2.1 二次情報源
15.1.2.2 一次情報源
15.2 著者情報

ページTOPに戻る



図表リスト

List of Tables
Table 1. Global Pathological Tissue Microtome Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Pathological Tissue Microtome Market Size Growth Rate by Level of Automation, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Pathological Tissue Microtome Market Size Growth Rate by Slice Thickness, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Pathological Tissue Microtome Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Pathological Tissue Microtome Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Pathological Tissue Microtome Revenue by Region (US$ Million), 2021-2026
Table 7. Global Pathological Tissue Microtome Revenue by Region (US$ Million), 2027-2032
Table 8. Global Pathological Tissue Microtome Sales Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (Units)
Table 9. Global Pathological Tissue Microtome Sales by Region (Units), 2021-2026
Table 10. Global Pathological Tissue Microtome Sales by Region (Units), 2027-2032
Table 11. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 12. Global Pathological Tissue Microtome Sales by Manufacturers (Units), 2021-2026
Table 13. Global Pathological Tissue Microtome Sales Share by Manufacturers (2021-2026)
Table 14. Global Pathological Tissue Microtome Revenue by Manufacturers (US$ Million), 2021-2026
Table 15. Global Pathological Tissue Microtome Revenue-Based Market Share by Manufacturers (2021-2026)
Table 16. Global Key Manufacturers’Ranking Shift (2024 vs. 2025) (Based on Revenue)
Table 17. Global Manufacturer by Tier (Tier 1, Tier 2, and Tier 3), based on Pathological Tissue Microtome Revenue, 2025
Table 18. Global Pathological Tissue Microtome Average Gross Margin (%) by Manufacturer (2021 vs 2025)
Table 19. Global Pathological Tissue Microtome Average Selling Price (ASP) by Manufacturers (US$/Unit), 2021-2026
Table 20. Key Manufacturers Pathological Tissue Microtome Manufacturing Base and Headquarters
Table 21. Global Pathological Tissue Microtome Market Concentration Ratio (CR5)
Table 22. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 23. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 24. Global Pathological Tissue Microtome Sales Volume by Type (Units), 2021-2026
Table 25. Global Pathological Tissue Microtome Sales Volume by Type (Units), 2027-2032
Table 26. Global Pathological Tissue Microtome Revenue by Type (US$ Million), 2021-2026
Table 27. Global Pathological Tissue Microtome Revenue by Type (US$ Million), 2027-2032
Table 28. Global Pathological Tissue Microtome Sales Volume by Level of Automation (Units), 2021-2026
Table 29. Global Pathological Tissue Microtome Sales Volume by Level of Automation (Units), 2027-2032
Table 30. Global Pathological Tissue Microtome Revenue by Level of Automation (US$ Million), 2021-2026
Table 31. Global Pathological Tissue Microtome Revenue by Level of Automation (US$ Million), 2027-2032
Table 32. Global Pathological Tissue Microtome Sales Volume by Slice Thickness (Units), 2021-2026
Table 33. Global Pathological Tissue Microtome Sales Volume by Slice Thickness (Units), 2027-2032
Table 34. Global Pathological Tissue Microtome Revenue by Slice Thickness (US$ Million), 2021-2026
Table 35. Global Pathological Tissue Microtome Revenue by Slice Thickness (US$ Million), 2027-2032
Table 36. Technical Specifications by Key Product Type
Table 37. Global Pathological Tissue Microtome Sales by Application (Units), 2021-2026
Table 38. Global Pathological Tissue Microtome Sales by Application (Units), 2027-2032
Table 39. Pathological Tissue Microtome High-Growth Sectors Demand CAGR (2026-2032)
Table 40. Global Pathological Tissue Microtome Revenue by Application (US$ Million), 2021-2026
Table 41. Global Pathological Tissue Microtome Revenue by Application (US$ Million), 2027-2032
Table 42. Top Customers by Region
Table 43. Top Customers by Application
Table 44. North America Pathological Tissue Microtome Growth Accelerators and Market Barriers
Table 45. North America Pathological Tissue Microtome Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 46. North America Pathological Tissue Microtome Sales (Units) by Country (2021 vs 2025 vs 2032)
Table 47. Europe Pathological Tissue Microtome Growth Accelerators and Market Barriers
Table 48. Europe Pathological Tissue Microtome Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 49. Europe Pathological Tissue Microtome Sales (Units) by Country (2021 vs 2025 vs 2032)
Table 50. Asia-Pacific Pathological Tissue Microtome Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 51. Asia-Pacific Pathological Tissue Microtome Sales (Units) by Country (2021 vs 2025 vs 2032)
Table 52. Asia-Pacific Pathological Tissue Microtome Growth Accelerators and Market Barriers
Table 53. Southeast Asia Pathological Tissue Microtome Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 54. Central and South America Pathological Tissue Microtome Investment Opportunities and Key Challenges
Table 55. Central and South America Pathological Tissue Microtome Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 56. Middle East and Africa Pathological Tissue Microtome Investment Opportunities and Key Challenges
Table 57. Middle East and Africa Pathological Tissue Microtome Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 58. Leica Biosystems Corporation Information
Table 59. Leica Biosystems Description and Major Businesses
Table 60. Leica Biosystems Product Models, Descriptions and Specifications
Table 61. Leica Biosystems Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 62. Leica Biosystems Sales Value Proportion by Product in 2025
Table 63. Leica Biosystems Sales Value Proportion by Application in 2025
Table 64. Leica Biosystems Sales Value Proportion by Geographic Area in 2025
Table 65. Leica Biosystems Pathological Tissue Microtome SWOT Analysis
Table 66. Leica Biosystems Recent Developments
Table 67. Sakura Finetek Corporation Information
Table 68. Sakura Finetek Description and Major Businesses
Table 69. Sakura Finetek Product Models, Descriptions and Specifications
Table 70. Sakura Finetek Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 71. Sakura Finetek Sales Value Proportion by Product in 2025
Table 72. Sakura Finetek Sales Value Proportion by Application in 2025
Table 73. Sakura Finetek Sales Value Proportion by Geographic Area in 2025
Table 74. Sakura Finetek Pathological Tissue Microtome SWOT Analysis
Table 75. Sakura Finetek Recent Developments
Table 76. Thermo Fisher Scientific Corporation Information
Table 77. Thermo Fisher Scientific Description and Major Businesses
Table 78. Thermo Fisher Scientific Product Models, Descriptions and Specifications
Table 79. Thermo Fisher Scientific Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Thermo Fisher Scientific Sales Value Proportion by Product in 2025
Table 81. Thermo Fisher Scientific Sales Value Proportion by Application in 2025
Table 82. Thermo Fisher Scientific Sales Value Proportion by Geographic Area in 2025
Table 83. Thermo Fisher Scientific Pathological Tissue Microtome SWOT Analysis
Table 84. Thermo Fisher Scientific Recent Developments
Table 85. Medite Corporation Information
Table 86. Medite Description and Major Businesses
Table 87. Medite Product Models, Descriptions and Specifications
Table 88. Medite Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 89. Medite Sales Value Proportion by Product in 2025
Table 90. Medite Sales Value Proportion by Application in 2025
Table 91. Medite Sales Value Proportion by Geographic Area in 2025
Table 92. Medite Pathological Tissue Microtome SWOT Analysis
Table 93. Medite Recent Developments
Table 94. Slee Medical Corporation Information
Table 95. Slee Medical Description and Major Businesses
Table 96. Slee Medical Product Models, Descriptions and Specifications
Table 97. Slee Medical Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 98. Slee Medical Sales Value Proportion by Product in 2025
Table 99. Slee Medical Sales Value Proportion by Application in 2025
Table 100. Slee Medical Sales Value Proportion by Geographic Area in 2025
Table 101. Slee Medical Pathological Tissue Microtome SWOT Analysis
Table 102. Slee Medical Recent Developments
Table 103. RMC Boeckeler Corporation Information
Table 104. RMC Boeckeler Description and Major Businesses
Table 105. RMC Boeckeler Product Models, Descriptions and Specifications
Table 106. RMC Boeckeler Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. RMC Boeckeler Recent Developments
Table 108. MICROS Austria Corporation Information
Table 109. MICROS Austria Description and Major Businesses
Table 110. MICROS Austria Product Models, Descriptions and Specifications
Table 111. MICROS Austria Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. MICROS Austria Recent Developments
Table 113. AGD Biomedicals Corporation Information
Table 114. AGD Biomedicals Description and Major Businesses
Table 115. AGD Biomedicals Product Models, Descriptions and Specifications
Table 116. AGD Biomedicals Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. AGD Biomedicals Recent Developments
Table 118. Amos Scientific Corporation Information
Table 119. Amos Scientific Description and Major Businesses
Table 120. Amos Scientific Product Models, Descriptions and Specifications
Table 121. Amos Scientific Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. Amos Scientific Recent Developments
Table 123. Bright Instrument Corporation Information
Table 124. Bright Instrument Description and Major Businesses
Table 125. Bright Instrument Product Models, Descriptions and Specifications
Table 126. Bright Instrument Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. Bright Instrument Recent Developments
Table 128. Diapath Corporation Information
Table 129. Diapath Description and Major Businesses
Table 130. Diapath Product Models, Descriptions and Specifications
Table 131. Diapath Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 132. Diapath Recent Developments
Table 133. Histo-Line Laboratories Corporation Information
Table 134. Histo-Line Laboratories Description and Major Businesses
Table 135. Histo-Line Laboratories Product Models, Descriptions and Specifications
Table 136. Histo-Line Laboratories Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 137. Histo-Line Laboratories Recent Developments
Table 138. Auxilab Corporation Information
Table 139. Auxilab Description and Major Businesses
Table 140. Auxilab Product Models, Descriptions and Specifications
Table 141. Auxilab Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 142. Auxilab Recent Developments
Table 143. Nanolytik Corporation Information
Table 144. Nanolytik Description and Major Businesses
Table 145. Nanolytik Product Models, Descriptions and Specifications
Table 146. Nanolytik Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 147. Nanolytik Recent Developments
Table 148. Orion Medic Corporation Information
Table 149. Orion Medic Description and Major Businesses
Table 150. Orion Medic Product Models, Descriptions and Specifications
Table 151. Orion Medic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 152. Orion Medic Recent Developments
Table 153. S.M. Scientific Corporation Information
Table 154. S.M. Scientific Description and Major Businesses
Table 155. S.M. Scientific Product Models, Descriptions and Specifications
Table 156. S.M. Scientific Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 157. S.M. Scientific Recent Developments
Table 158. RWD Corporation Information
Table 159. RWD Description and Major Businesses
Table 160. RWD Product Models, Descriptions and Specifications
Table 161. RWD Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 162. RWD Recent Developments
Table 163. Dakewe Corporation Information
Table 164. Dakewe Description and Major Businesses
Table 165. Dakewe Product Models, Descriptions and Specifications
Table 166. Dakewe Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 167. Dakewe Recent Developments
Table 168. YIDI Medical Corporation Information
Table 169. YIDI Medical Description and Major Businesses
Table 170. YIDI Medical Product Models, Descriptions and Specifications
Table 171. YIDI Medical Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 172. YIDI Medical Recent Developments
Table 173. Key Raw Materials Distribution
Table 174. Raw Materials Key Suppliers
Table 175. Critical Raw Material Supplier Concentration (2025) & Risk Index
Table 176. Milestones in Production Technology Evolution
Table 177. Distributors List
Table 178. Market Trends and Market Evolution
Table 179. Market Drivers and Opportunities
Table 180. Market Challenges, Risks, and Restraints
Table 181. Research Programs/Design for This Report
Table 182. Key Data Information from Secondary Sources
Table 183. Key Data Information from Primary Sources

List of Figures
Figure 1. Pathological Tissue Microtome Product Picture
Figure 2. Global Pathological Tissue Microtome Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 3. Rotary Microtomes Product Picture
Figure 4. Cryostat Microtomes Product Picture
Figure 5. Sliding Microtomes Product Picture
Figure 6. Others Product Picture
Figure 7. Global Pathological Tissue Microtome Market Size Growth Rate by Level of Automation, 2021 vs 2025 vs 2032 (US$ Million)
Figure 8. Manual Microtome Product Picture
Figure 9. Semi-automated Microtome Product Picture
Figure 10. Fully Automated Microtome Product Picture
Figure 11. Global Pathological Tissue Microtome Market Size Growth Rate by Slice Thickness, 2021 vs 2025 vs 2032 (US$ Million)
Figure 12. 1–10 μm Product Picture
Figure 13. 0.1–1 μm Product Picture
Figure 14. 20–100 nm Product Picture
Figure 15. Global Pathological Tissue Microtome Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 16. Pathological Diagnosis
Figure 17. Pharmaceuticals
Figure 18. Scientific Research
Figure 19. Others
Figure 20. Pathological Tissue Microtome Report Years Considered
Figure 21. Global Pathological Tissue Microtome Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 22. Global Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 23. Global Pathological Tissue Microtome Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 24. Global Pathological Tissue Microtome Revenue-Based Market Share by Region (2021-2032)
Figure 25. Global Pathological Tissue Microtome Sales (Units), 2021-2032
Figure 26. Global Pathological Tissue Microtome Sales (CAGR) by Region: 2021 vs 2025 vs 2032 (Units)
Figure 27. Global Pathological Tissue Microtome Sales Market Share by Region (2021-2032)
Figure 28. Top 5 and Top 10 Manufacturers Pathological Tissue Microtome Sales Volume Market Share in 2025
Figure 29. Global Pathological Tissue Microtome Revenue-Based Market Share Ranking (2025)
Figure 30. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 31. Rotary Microtomes Revenue-Based Market Share by Manufacturer in 2025
Figure 32. Cryostat Microtomes Revenue-Based Market Share by Manufacturer in 2025
Figure 33. Sliding Microtomes Revenue-Based Market Share by Manufacturer in 2025
Figure 34. Others Revenue-Based Market Share by Manufacturer in 2025
Figure 35. Global Pathological Tissue Microtome Sales Volume-Based Market Share by Type (2021-2032)
Figure 36. Global Pathological Tissue Microtome Revenue-Based Market Share by Type (2021-2032)
Figure 37. Global Pathological Tissue Microtome ASP by Type (US$/Unit), 2021-2032
Figure 38. Global Pathological Tissue Microtome Sales Volume-Based Market Share by Level of Automation (2021-2032)
Figure 39. Global Pathological Tissue Microtome Revenue-Based Market Share by Level of Automation (2021-2032)
Figure 40. Global Pathological Tissue Microtome ASP by Level of Automation (US$/Unit), 2021-2032
Figure 41. Global Pathological Tissue Microtome Sales Volume-Based Market Share by Slice Thickness (2021-2032)
Figure 42. Global Pathological Tissue Microtome Revenue-Based Market Share by Slice Thickness (2021-2032)
Figure 43. Global Pathological Tissue Microtome ASP by Slice Thickness (US$/Unit), 2021-2032
Figure 44. Global Pathological Tissue Microtome Sales Market Share by Application (2021-2032)
Figure 45. Global Pathological Tissue Microtome Revenue-Based Market Share by Application (2021-2032)
Figure 46. Global Pathological Tissue Microtome ASP by Application (US$/Unit), 2021-2032
Figure 47. North America Pathological Tissue Microtome Sales YoY (Units), 2021-2032
Figure 48. North America Pathological Tissue Microtome Revenue YoY (US$ Million), 2021-2032
Figure 49. North America Top 5 Manufacturers Pathological Tissue Microtome Sales Revenue (US$ Million) in 2025
Figure 50. North America Pathological Tissue Microtome Sales Volume (Units) by Application (2021-2032)
Figure 51. North America Pathological Tissue Microtome Sales Revenue (US$ Million) by Application (2021-2032)
Figure 52. US Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 53. Canada Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 54. Mexico Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 55. Europe Pathological Tissue Microtome Sales YoY (Units), 2021-2032
Figure 56. Europe Pathological Tissue Microtome Revenue YoY (US$ Million), 2021-2032
Figure 57. Europe Top 5 Manufacturers Pathological Tissue Microtome Sales Revenue (US$ Million) in 2025
Figure 58. Europe Pathological Tissue Microtome Sales Volume (Units) by Application (2021-2032)
Figure 59. Europe Pathological Tissue Microtome Sales Revenue (US$ Million) by Application (2021-2032)
Figure 60. Germany Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 61. France Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 62. U.K. Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 63. Italy Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 64. Russia Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 65. Asia-Pacific Pathological Tissue Microtome Sales YoY (Units), 2021-2032
Figure 66. Asia-Pacific Pathological Tissue Microtome Revenue YoY (US$ Million), 2021-2032
Figure 67. Asia-Pacific Top 8 Manufacturers Pathological Tissue Microtome Sales Revenue (US$ Million) in 2025
Figure 68. Asia-Pacific Pathological Tissue Microtome Sales Volume (Units) by Application (2021-2032)
Figure 69. Asia-Pacific Pathological Tissue Microtome Sales Revenue (US$ Million) by Application (2021-2032)
Figure 70. Indonesia Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 71. Japan Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 72. South Korea Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 73. China Taiwan Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 74. India Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 75. Central and South America Pathological Tissue Microtome Sales YoY (Units), 2021-2032
Figure 76. Central and South America Pathological Tissue Microtome Revenue YoY (US$ Million), 2021-2032
Figure 77. Central and South America Top 5 Manufacturers Pathological Tissue Microtome Sales Revenue (US$ Million) in 2025
Figure 78. Central and South America Pathological Tissue Microtome Sales Volume (Units) by Application (2021-2032)
Figure 79. Central and South America Pathological Tissue Microtome Sales Revenue (US$ Million) by Application (2021-2032)
Figure 80. Brazil Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 81. Argentina Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 82. Middle East, and Africa Pathological Tissue Microtome Sales YoY (Units), 2021-2032
Figure 83. Middle East and Africa Pathological Tissue Microtome Revenue YoY (US$ Million), 2021-2032
Figure 84. Middle East and Africa Top 5 Manufacturers Pathological Tissue Microtome Sales Revenue (US$ Million) in 2025
Figure 85. Middle East and Africa Pathological Tissue Microtome Sales Volume (Units) by Application (2021-2032)
Figure 86. Middle East and Africa Pathological Tissue Microtome Sales Revenue (US$ Million) by Application (2021-2032)
Figure 87. GCC Countries Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 88. Turkey Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 89. Egypt Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 90. South Africa Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 91. Pathological Tissue Microtome Industry Chain Mapping
Figure 92. Regional Pathological Tissue Microtome Manufacturing Base Distribution (%)
Figure 93. Global Pathological Tissue Microtome Production Market Share by Region (2021-2032)
Figure 94. Pathological Tissue Microtome Production Process
Figure 95. Regional Pathological Tissue Microtome Production Cost Structure
Figure 96. Channels of Distribution (Direct Vs Distribution)
Figure 97. Bottom-up and Top-down Approaches for This Report
Figure 98. Data Triangulation
Figure 99. Key Executives Interviewed

　

ページTOPに戻る


　

Summary

The global Pathological Tissue Microtome market is projected to grow from US$ 228 million in 2025 to US$ 291 million by 2032, at a CAGR of 3.6% (2026-2032), driven by critical product segments and diverse end‑use applications.
A Pathological Tissue Microtome is a precision instrument used in medical laboratories to cut extremely thin sections of biological tissue for microscopic examination, primarily in the diagnosis of diseases. It is essential in histopathology, where accurate and consistent tissue slicing is critical for identifying cellular abnormalities, tumors, and other pathological changes. The microtome allows technicians to prepare samples that are typically embedded in paraffin or frozen, producing slices just a few microns thick. These sections are then stained and analyzed under a microscope. Pathological tissue microtomes come in various types, including rotary, sliding, cryostat, and ultramicrotomes, each suited for specific sample types and diagnostic requirements.
Key Findings
In 2025, global sales volume for pathological microtomes is projected to reach 35,000 units, with a production capacity of approximately 50,000 units, an average selling price of $6,500 per unit, and an average gross margin of 50%–60%.
Paraffin Microtome represented the largest product segment by shipment volume
Pathology diagnosis remained the primary application market globally
Market Trends
The Pathological Tissue Microtome market is moving toward higher precision, automation, and integration with digital pathology systems. Traditional tissue sectioning workflows are increasingly being upgraded through semi-automated and automated technologies that improve section consistency, reduce operator dependence, and enhance laboratory productivity. As pathology laboratories adopt digital imaging, artificial intelligence-assisted diagnosis, and standardized workflows, demand is shifting toward tissue sectioning systems with improved accuracy, reproducibility, and workflow compatibility. In addition, increasing applications in precision medicine, molecular pathology, biomedical research, and pharmaceutical development are encouraging manufacturers to develop more specialized systems capable of handling diverse tissue preparation requirements.
Market Dynamics
Drivers
The increasing demand for pathological diagnosis, growth of cancer screening programs, expansion of hospital pathology capacity, and rising investment in biomedical research are key factors driving the adoption of Pathological Tissue Microtome. The development of digital pathology and laboratory automation is further supporting demand for standardized and high-quality tissue preparation equipment.
Restraints
The market is influenced by relatively high equipment costs, professional operation requirements, and differences in laboratory infrastructure across regions. Advanced automated tissue sectioning systems require higher investment and maintenance capabilities, which may limit adoption among smaller laboratories and institutions with limited budgets.
Opportunities
The expansion of digital pathology, precision medicine, artificial intelligence-assisted diagnosis, and pharmaceutical research creates new opportunities for Pathological Tissue Microtome manufacturers. Integration with automated laboratory platforms, intelligent sample preparation workflows, and improved cutting technologies may enhance equipment value and expand applications in clinical and research environments.
Challenges
The industry faces challenges related to maintaining consistent section quality, improving automation reliability, and meeting diverse requirements from clinical and research users. Increasing competition among pathology equipment providers and the demand for integrated diagnostic workflows require manufacturers to continuously improve product performance, compatibility, and service capabilities.
Industry Chain Analysis
The Pathological Tissue Microtome industry chain consists of upstream precision component suppliers, midstream equipment manufacturers, and downstream medical, research, and pharmaceutical users. Upstream suppliers provide precision mechanical components, cutting blades, motors, control systems, temperature control modules, and structural materials. Midstream manufacturers integrate these components into complete tissue sectioning systems with sample positioning, thickness adjustment, cutting control, and operational management functions.
The major value creation areas are concentrated in mechanical precision, sectioning stability, automation capability, and compatibility with pathology workflows. Compared with general laboratory equipment, Pathological Tissue Microtome creates additional value through specialized consumables, maintenance services, accessories, and integration with digital pathology platforms. Downstream users mainly include hospitals, pathology laboratories, medical testing centers, universities, research institutions, and pharmaceutical companies.
Segment Insights
The Pathological Tissue Microtome market can be segmented by sectioning technology, automation level, sample preparation method, and application field. Paraffin Microtome represents the largest segment by shipment volume due to its extensive use in routine histopathological diagnosis. Cryostat Microtome represents a specialized high-value segment supported by demand for rapid intraoperative diagnosis and frozen tissue analysis.
From an automation perspective, manual and semi-automated systems currently account for a significant proportion of installed equipment because of their mature clinical applications and cost advantages. Fully automated tissue sectioning systems represent a higher-value development direction, especially for large pathology centers requiring standardized operation and higher laboratory efficiency. Research-oriented systems, including vibrating and ultrathin sectioning technologies, provide additional opportunities in specialized biomedical applications.
Downstream Market Opportunities
Pathological Tissue Microtome is mainly applied in medical diagnosis, biomedical research, and pharmaceutical development scenarios requiring standardized tissue sample preparation. Hospitals and pathology laboratories use these systems for tumor diagnosis, biopsy examination, tissue morphology analysis, and routine histopathological testing. Research institutions apply them in cell biology, neuroscience, and tissue structure studies, while pharmaceutical companies use them for drug evaluation and toxicology research. Future opportunities are expected from increasing diagnostic demand, expansion of digital pathology, and the continuous development of precision medicine.
Regional Insights
North America represents one of the leading regional markets for Pathological Tissue Microtome due to advanced healthcare infrastructure, established pathology laboratory systems, and high adoption of digital pathology technologies. Hospitals, diagnostic centers, and research institutions in the region maintain stable demand for high-performance tissue sectioning equipment.
Europe also holds an important market position supported by mature medical research capabilities, advanced pathology services, and pharmaceutical development activities. Asia-Pacific is becoming a key growth region driven by healthcare infrastructure expansion, increasing diagnostic capacity, and rising biomedical research investment. Regional differences are mainly reflected in laboratory modernization levels, healthcare investment, and adoption of advanced pathology technologies.
Competitive Landscape Analysis
The Pathological Tissue Microtome market is characterized by competition among specialized pathology equipment manufacturers and broader life science instrument companies. Competitive advantages mainly depend on sectioning precision, equipment reliability, automation capability, product portfolio, clinical application experience, and global service networks. Companies with comprehensive pathology workflow solutions have stronger positions in hospital and diagnostic laboratory markets, while specialized manufacturers maintain competitiveness in research and advanced sample preparation fields. The market is gradually evolving toward integrated pathology solutions, higher automation levels, improved sectioning consistency, and stronger compatibility with digital pathology ecosystems.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Pathological Tissue Microtome market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers (sales volume, revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Leica Biosystems
Sakura Finetek
Thermo Fisher Scientific
Medite
Slee Medical
RMC Boeckeler
MICROS Austria
AGD Biomedicals
Amos Scientific
Bright Instrument
Diapath
Histo-Line Laboratories
Auxilab
Nanolytik
Orion Medic
S.M. Scientific
RWD
Dakewe
YIDI Medical
Segment by Type
Rotary Microtomes
Cryostat Microtomes
Sliding Microtomes
Others
Segment by Level of Automation
Manual Microtome
Semi-automated Microtome
Fully Automated Microtome
Segment by Slice Thickness
1–10 μm
0.1–1 μm
20–100 nm
Segment by Application
Pathological Diagnosis
Pharmaceuticals
Scientific Research
Others
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
Europe
Germany
France
U.K.
Italy
Russia
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Pathological Tissue Microtome study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape: ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down sales and revenue by Application and country, profiles key manufacturers and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional sales, revenue and market by Application and manufacturers, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies sales and revenue by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures sales and revenue by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates sales and revenue by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth: details product specs, sales, revenue, margins; top manufactures 2025 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments
Chapter 12: Supply chain: analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.


ページTOPに戻る


Table of Contents

1 Study Coverage
1.1 Introduction to Pathological Tissue Microtome: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Pathological Tissue Microtome Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Rotary Microtomes
1.2.3 Cryostat Microtomes
1.2.4 Sliding Microtomes
1.2.5 Others
1.3 Market Segmentation by Level of Automation
1.3.1 Global Pathological Tissue Microtome Market Size by Level of Automation, 2021 vs 2025 vs 2032
1.3.2 Manual Microtome
1.3.3 Semi-automated Microtome
1.3.4 Fully Automated Microtome
1.4 Market Segmentation by Slice Thickness
1.4.1 Global Pathological Tissue Microtome Market Size by Slice Thickness, 2021 vs 2025 vs 2032
1.4.2 1–10 μm
1.4.3 0.1–1 μm
1.4.4 20–100 nm
1.5 Market Segmentation by Application
1.5.1 Global Pathological Tissue Microtome Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Pathological Diagnosis
1.5.3 Pharmaceuticals
1.5.4 Scientific Research
1.5.5 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Pathological Tissue Microtome Revenue Estimates and Forecasts (2021-2032)
2.2 Global Pathological Tissue Microtome Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.3 Global Pathological Tissue Microtome Sales Estimates and Forecasts (2021-2032)
2.4 Global Pathological Tissue Microtome Sales by Region
2.4.1 Sales Comparison: 2021 vs 2025 vs 2032
2.4.2 Historical and Forecasted Sales by Region (2021-2032)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2021-2032)

3 Competitive Landscape
3.1 Global Pathological Tissue Microtome Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2021-2026)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2025)
3.2 Global Pathological Tissue Microtome Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2021-2026)
3.2.2 Global Key Manufacturer Revenue Ranking (2024 vs. 2025)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2021 vs 2025)
3.3.2 Manufacturer-Level Price Trends (2021-2026)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Key Manufacturers Market Share by Product Type
3.5.1 Rotary Microtomes: Market Share by Key Manufacturers
3.5.2 Cryostat Microtomes: Market Share by Key Manufacturers
3.5.3 Sliding Microtomes: Market Share by Key Manufacturers
3.5.4 Others: Market Share by Key Manufacturers
3.6 Global Pathological Tissue Microtome Market Concentration and Dynamics
3.6.1 Global Market Concentration
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Product Segmentation
4.1 Global Pathological Tissue Microtome Sales Performance by Type
4.1.1 Global Pathological Tissue Microtome Sales Volume by Type (2021-2032)
4.1.2 Global Pathological Tissue Microtome Revenue by Type (2021-2032)
4.1.3 Global Average Selling Price (ASP) Trends by Type (2021-2032)
4.2 Global Pathological Tissue Microtome Sales Performance by Level of Automation
4.2.1 Global Pathological Tissue Microtome Sales Volume by Level of Automation (2021-2032)
4.2.2 Global Pathological Tissue Microtome Revenue by Level of Automation (2021-2032)
4.2.3 Global Average Selling Price (ASP) Trends by Level of Automation (2021-2032)
4.3 Global Pathological Tissue Microtome Sales Performance by Slice Thickness
4.3.1 Global Pathological Tissue Microtome Sales Volume by Slice Thickness (2021-2032)
4.3.2 Global Pathological Tissue Microtome Revenue by Slice Thickness (2021-2032)
4.3.3 Global Average Selling Price (ASP) Trends by Slice Thickness (2021-2032)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Pathological Tissue Microtome Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2021-2032)
5.1.2 Global Sales Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Pathological Tissue Microtome Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.2.2 Revenue-Based Market Share by Application (2021-2032)
5.3 Global Pricing Dynamics by Application (2021-2032)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application

6 North America
6.1 North America Sales Volume and Revenue (2021-2032)
6.2 North America Key Manufacturers Sales Revenue in 2025
6.3 North America Pathological Tissue Microtome Sales and Revenue by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Pathological Tissue Microtome Market Size by Country
6.5.1 North America Revenue by Country
6.5.2 North America Sales Trends by Country
6.5.3 US
6.5.4 Canada
6.5.5 Mexico

7 Europe
7.1 Europe Sales Volume and Revenue (2021-2032)
7.2 Europe Key Manufacturers Sales Revenue in 2025
7.3 Europe Pathological Tissue Microtome Sales and Revenue by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Pathological Tissue Microtome Market Size by Country
7.5.1 Europe Revenue by Country
7.5.2 Europe Sales Trends by Country
7.5.3 Germany
7.5.4 France
7.5.5 U.K.
7.5.6 Italy
7.5.7 Russia

8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2021-2032)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2025
8.3 Asia-Pacific Pathological Tissue Microtome Sales and Revenue by Application (2021-2032)
8.4 Asia-Pacific Pathological Tissue Microtome Market Size by Region
8.4.1 Asia-Pacific Revenue by Region
8.4.2 Asia-Pacific Sales Trends by Region
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Southeast Asia
8.6.1 Southeast Asia Revenue by Country (2021 vs 2025 vs 2032)
8.6.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.7 China
8.8 Japan
8.9 South Korea
8.10 China Taiwan
8.11 India

9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2021-2032)
9.2 Central and South America Key Manufacturers Sales Revenue in 2025
9.3 Central and South America Pathological Tissue Microtome Sales and Revenue by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Pathological Tissue Microtome Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2021-2032)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2025
10.3 Middle East and Africa Pathological Tissue Microtome Sales and Revenue by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Pathological Tissue Microtome Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Turkey
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Leica Biosystems
11.1.1 Leica Biosystems Corporation Information
11.1.2 Leica Biosystems Business Overview
11.1.3 Leica Biosystems Pathological Tissue Microtome Product Models, Descriptions and Specifications
11.1.4 Leica Biosystems Pathological Tissue Microtome Sales, Price, Revenue and Gross Margin (2021-2026)
11.1.5 Leica Biosystems Pathological Tissue Microtome Sales by Product in 2025
11.1.6 Leica Biosystems Pathological Tissue Microtome Sales by Application in 2025
11.1.7 Leica Biosystems Pathological Tissue Microtome Sales by Geographic Area in 2025
11.1.8 Leica Biosystems Pathological Tissue Microtome SWOT Analysis
11.1.9 Leica Biosystems Recent Developments
11.2 Sakura Finetek
11.2.1 Sakura Finetek Corporation Information
11.2.2 Sakura Finetek Business Overview
11.2.3 Sakura Finetek Pathological Tissue Microtome Product Models, Descriptions and Specifications
11.2.4 Sakura Finetek Pathological Tissue Microtome Sales, Price, Revenue and Gross Margin (2021-2026)
11.2.5 Sakura Finetek Pathological Tissue Microtome Sales by Product in 2025
11.2.6 Sakura Finetek Pathological Tissue Microtome Sales by Application in 2025
11.2.7 Sakura Finetek Pathological Tissue Microtome Sales by Geographic Area in 2025
11.2.8 Sakura Finetek Pathological Tissue Microtome SWOT Analysis
11.2.9 Sakura Finetek Recent Developments
11.3 Thermo Fisher Scientific
11.3.1 Thermo Fisher Scientific Corporation Information
11.3.2 Thermo Fisher Scientific Business Overview
11.3.3 Thermo Fisher Scientific Pathological Tissue Microtome Product Models, Descriptions and Specifications
11.3.4 Thermo Fisher Scientific Pathological Tissue Microtome Sales, Price, Revenue and Gross Margin (2021-2026)
11.3.5 Thermo Fisher Scientific Pathological Tissue Microtome Sales by Product in 2025
11.3.6 Thermo Fisher Scientific Pathological Tissue Microtome Sales by Application in 2025
11.3.7 Thermo Fisher Scientific Pathological Tissue Microtome Sales by Geographic Area in 2025
11.3.8 Thermo Fisher Scientific Pathological Tissue Microtome SWOT Analysis
11.3.9 Thermo Fisher Scientific Recent Developments
11.4 Medite
11.4.1 Medite Corporation Information
11.4.2 Medite Business Overview
11.4.3 Medite Pathological Tissue Microtome Product Models, Descriptions and Specifications
11.4.4 Medite Pathological Tissue Microtome Sales, Price, Revenue and Gross Margin (2021-2026)
11.4.5 Medite Pathological Tissue Microtome Sales by Product in 2025
11.4.6 Medite Pathological Tissue Microtome Sales by Application in 2025
11.4.7 Medite Pathological Tissue Microtome Sales by Geographic Area in 2025
11.4.8 Medite Pathological Tissue Microtome SWOT Analysis
11.4.9 Medite Recent Developments
11.5 Slee Medical
11.5.1 Slee Medical Corporation Information
11.5.2 Slee Medical Business Overview
11.5.3 Slee Medical Pathological Tissue Microtome Product Models, Descriptions and Specifications
11.5.4 Slee Medical Pathological Tissue Microtome Sales, Price, Revenue and Gross Margin (2021-2026)
11.5.5 Slee Medical Pathological Tissue Microtome Sales by Product in 2025
11.5.6 Slee Medical Pathological Tissue Microtome Sales by Application in 2025
11.5.7 Slee Medical Pathological Tissue Microtome Sales by Geographic Area in 2025
11.5.8 Slee Medical Pathological Tissue Microtome SWOT Analysis
11.5.9 Slee Medical Recent Developments
11.6 RMC Boeckeler
11.6.1 RMC Boeckeler Corporation Information
11.6.2 RMC Boeckeler Business Overview
11.6.3 RMC Boeckeler Pathological Tissue Microtome Product Models, Descriptions and Specifications
11.6.4 RMC Boeckeler Pathological Tissue Microtome Sales, Price, Revenue and Gross Margin (2021-2026)
11.6.5 RMC Boeckeler Recent Developments
11.7 MICROS Austria
11.7.1 MICROS Austria Corporation Information
11.7.2 MICROS Austria Business Overview
11.7.3 MICROS Austria Pathological Tissue Microtome Product Models, Descriptions and Specifications
11.7.4 MICROS Austria Pathological Tissue Microtome Sales, Price, Revenue and Gross Margin (2021-2026)
11.7.5 MICROS Austria Recent Developments
11.8 AGD Biomedicals
11.8.1 AGD Biomedicals Corporation Information
11.8.2 AGD Biomedicals Business Overview
11.8.3 AGD Biomedicals Pathological Tissue Microtome Product Models, Descriptions and Specifications
11.8.4 AGD Biomedicals Pathological Tissue Microtome Sales, Price, Revenue and Gross Margin (2021-2026)
11.8.5 AGD Biomedicals Recent Developments
11.9 Amos Scientific
11.9.1 Amos Scientific Corporation Information
11.9.2 Amos Scientific Business Overview
11.9.3 Amos Scientific Pathological Tissue Microtome Product Models, Descriptions and Specifications
11.9.4 Amos Scientific Pathological Tissue Microtome Sales, Price, Revenue and Gross Margin (2021-2026)
11.9.5 Amos Scientific Recent Developments
11.10 Bright Instrument
11.10.1 Bright Instrument Corporation Information
11.10.2 Bright Instrument Business Overview
11.10.3 Bright Instrument Pathological Tissue Microtome Product Models, Descriptions and Specifications
11.10.4 Bright Instrument Pathological Tissue Microtome Sales, Price, Revenue and Gross Margin (2021-2026)
11.10.5 Bright Instrument Recent Developments
11.11 Diapath
11.11.1 Diapath Corporation Information
11.11.2 Diapath Business Overview
11.11.3 Diapath Pathological Tissue Microtome Product Models, Descriptions and Specifications
11.11.4 Diapath Pathological Tissue Microtome Sales, Price, Revenue and Gross Margin (2021-2026)
11.11.5 Diapath Recent Developments
11.12 Histo-Line Laboratories
11.12.1 Histo-Line Laboratories Corporation Information
11.12.2 Histo-Line Laboratories Business Overview
11.12.3 Histo-Line Laboratories Pathological Tissue Microtome Product Models, Descriptions and Specifications
11.12.4 Histo-Line Laboratories Pathological Tissue Microtome Sales, Price, Revenue and Gross Margin (2021-2026)
11.12.5 Histo-Line Laboratories Recent Developments
11.13 Auxilab
11.13.1 Auxilab Corporation Information
11.13.2 Auxilab Business Overview
11.13.3 Auxilab Pathological Tissue Microtome Product Models, Descriptions and Specifications
11.13.4 Auxilab Pathological Tissue Microtome Sales, Price, Revenue and Gross Margin (2021-2026)
11.13.5 Auxilab Recent Developments
11.14 Nanolytik
11.14.1 Nanolytik Corporation Information
11.14.2 Nanolytik Business Overview
11.14.3 Nanolytik Pathological Tissue Microtome Product Models, Descriptions and Specifications
11.14.4 Nanolytik Pathological Tissue Microtome Sales, Price, Revenue and Gross Margin (2021-2026)
11.14.5 Nanolytik Recent Developments
11.15 Orion Medic
11.15.1 Orion Medic Corporation Information
11.15.2 Orion Medic Business Overview
11.15.3 Orion Medic Pathological Tissue Microtome Product Models, Descriptions and Specifications
11.15.4 Orion Medic Pathological Tissue Microtome Sales, Price, Revenue and Gross Margin (2021-2026)
11.15.5 Orion Medic Recent Developments
11.16 S.M. Scientific
11.16.1 S.M. Scientific Corporation Information
11.16.2 S.M. Scientific Business Overview
11.16.3 S.M. Scientific Pathological Tissue Microtome Product Models, Descriptions and Specifications
11.16.4 S.M. Scientific Pathological Tissue Microtome Sales, Price, Revenue and Gross Margin (2021-2026)
11.16.5 S.M. Scientific Recent Developments
11.17 RWD
11.17.1 RWD Corporation Information
11.17.2 RWD Business Overview
11.17.3 RWD Pathological Tissue Microtome Product Models, Descriptions and Specifications
11.17.4 RWD Pathological Tissue Microtome Sales, Price, Revenue and Gross Margin (2021-2026)
11.17.5 RWD Recent Developments
11.18 Dakewe
11.18.1 Dakewe Corporation Information
11.18.2 Dakewe Business Overview
11.18.3 Dakewe Pathological Tissue Microtome Product Models, Descriptions and Specifications
11.18.4 Dakewe Pathological Tissue Microtome Sales, Price, Revenue and Gross Margin (2021-2026)
11.18.5 Dakewe Recent Developments
11.19 YIDI Medical
11.19.1 YIDI Medical Corporation Information
11.19.2 YIDI Medical Business Overview
11.19.3 YIDI Medical Pathological Tissue Microtome Product Models, Descriptions and Specifications
11.19.4 YIDI Medical Pathological Tissue Microtome Sales, Price, Revenue and Gross Margin (2021-2026)
11.19.5 YIDI Medical Recent Developments

12 Value Chain and Supply-Chain Analysis
12.1 Pathological Tissue Microtome Industry Chain
12.2 Pathological Tissue Microtome Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Pathological Tissue Microtome Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2021-2032)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Pathological Tissue Microtome Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Pathological Tissue Microtome Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
13.4 Impact of U.S. Tariffs

14 Key Findings in the Global Pathological Tissue Microtome Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る



List of Tables/Graphs

List of Tables
Table 1. Global Pathological Tissue Microtome Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Pathological Tissue Microtome Market Size Growth Rate by Level of Automation, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Pathological Tissue Microtome Market Size Growth Rate by Slice Thickness, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Pathological Tissue Microtome Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Pathological Tissue Microtome Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Pathological Tissue Microtome Revenue by Region (US$ Million), 2021-2026
Table 7. Global Pathological Tissue Microtome Revenue by Region (US$ Million), 2027-2032
Table 8. Global Pathological Tissue Microtome Sales Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (Units)
Table 9. Global Pathological Tissue Microtome Sales by Region (Units), 2021-2026
Table 10. Global Pathological Tissue Microtome Sales by Region (Units), 2027-2032
Table 11. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 12. Global Pathological Tissue Microtome Sales by Manufacturers (Units), 2021-2026
Table 13. Global Pathological Tissue Microtome Sales Share by Manufacturers (2021-2026)
Table 14. Global Pathological Tissue Microtome Revenue by Manufacturers (US$ Million), 2021-2026
Table 15. Global Pathological Tissue Microtome Revenue-Based Market Share by Manufacturers (2021-2026)
Table 16. Global Key Manufacturers’Ranking Shift (2024 vs. 2025) (Based on Revenue)
Table 17. Global Manufacturer by Tier (Tier 1, Tier 2, and Tier 3), based on Pathological Tissue Microtome Revenue, 2025
Table 18. Global Pathological Tissue Microtome Average Gross Margin (%) by Manufacturer (2021 vs 2025)
Table 19. Global Pathological Tissue Microtome Average Selling Price (ASP) by Manufacturers (US$/Unit), 2021-2026
Table 20. Key Manufacturers Pathological Tissue Microtome Manufacturing Base and Headquarters
Table 21. Global Pathological Tissue Microtome Market Concentration Ratio (CR5)
Table 22. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 23. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 24. Global Pathological Tissue Microtome Sales Volume by Type (Units), 2021-2026
Table 25. Global Pathological Tissue Microtome Sales Volume by Type (Units), 2027-2032
Table 26. Global Pathological Tissue Microtome Revenue by Type (US$ Million), 2021-2026
Table 27. Global Pathological Tissue Microtome Revenue by Type (US$ Million), 2027-2032
Table 28. Global Pathological Tissue Microtome Sales Volume by Level of Automation (Units), 2021-2026
Table 29. Global Pathological Tissue Microtome Sales Volume by Level of Automation (Units), 2027-2032
Table 30. Global Pathological Tissue Microtome Revenue by Level of Automation (US$ Million), 2021-2026
Table 31. Global Pathological Tissue Microtome Revenue by Level of Automation (US$ Million), 2027-2032
Table 32. Global Pathological Tissue Microtome Sales Volume by Slice Thickness (Units), 2021-2026
Table 33. Global Pathological Tissue Microtome Sales Volume by Slice Thickness (Units), 2027-2032
Table 34. Global Pathological Tissue Microtome Revenue by Slice Thickness (US$ Million), 2021-2026
Table 35. Global Pathological Tissue Microtome Revenue by Slice Thickness (US$ Million), 2027-2032
Table 36. Technical Specifications by Key Product Type
Table 37. Global Pathological Tissue Microtome Sales by Application (Units), 2021-2026
Table 38. Global Pathological Tissue Microtome Sales by Application (Units), 2027-2032
Table 39. Pathological Tissue Microtome High-Growth Sectors Demand CAGR (2026-2032)
Table 40. Global Pathological Tissue Microtome Revenue by Application (US$ Million), 2021-2026
Table 41. Global Pathological Tissue Microtome Revenue by Application (US$ Million), 2027-2032
Table 42. Top Customers by Region
Table 43. Top Customers by Application
Table 44. North America Pathological Tissue Microtome Growth Accelerators and Market Barriers
Table 45. North America Pathological Tissue Microtome Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 46. North America Pathological Tissue Microtome Sales (Units) by Country (2021 vs 2025 vs 2032)
Table 47. Europe Pathological Tissue Microtome Growth Accelerators and Market Barriers
Table 48. Europe Pathological Tissue Microtome Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 49. Europe Pathological Tissue Microtome Sales (Units) by Country (2021 vs 2025 vs 2032)
Table 50. Asia-Pacific Pathological Tissue Microtome Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 51. Asia-Pacific Pathological Tissue Microtome Sales (Units) by Country (2021 vs 2025 vs 2032)
Table 52. Asia-Pacific Pathological Tissue Microtome Growth Accelerators and Market Barriers
Table 53. Southeast Asia Pathological Tissue Microtome Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 54. Central and South America Pathological Tissue Microtome Investment Opportunities and Key Challenges
Table 55. Central and South America Pathological Tissue Microtome Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 56. Middle East and Africa Pathological Tissue Microtome Investment Opportunities and Key Challenges
Table 57. Middle East and Africa Pathological Tissue Microtome Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 58. Leica Biosystems Corporation Information
Table 59. Leica Biosystems Description and Major Businesses
Table 60. Leica Biosystems Product Models, Descriptions and Specifications
Table 61. Leica Biosystems Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 62. Leica Biosystems Sales Value Proportion by Product in 2025
Table 63. Leica Biosystems Sales Value Proportion by Application in 2025
Table 64. Leica Biosystems Sales Value Proportion by Geographic Area in 2025
Table 65. Leica Biosystems Pathological Tissue Microtome SWOT Analysis
Table 66. Leica Biosystems Recent Developments
Table 67. Sakura Finetek Corporation Information
Table 68. Sakura Finetek Description and Major Businesses
Table 69. Sakura Finetek Product Models, Descriptions and Specifications
Table 70. Sakura Finetek Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 71. Sakura Finetek Sales Value Proportion by Product in 2025
Table 72. Sakura Finetek Sales Value Proportion by Application in 2025
Table 73. Sakura Finetek Sales Value Proportion by Geographic Area in 2025
Table 74. Sakura Finetek Pathological Tissue Microtome SWOT Analysis
Table 75. Sakura Finetek Recent Developments
Table 76. Thermo Fisher Scientific Corporation Information
Table 77. Thermo Fisher Scientific Description and Major Businesses
Table 78. Thermo Fisher Scientific Product Models, Descriptions and Specifications
Table 79. Thermo Fisher Scientific Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Thermo Fisher Scientific Sales Value Proportion by Product in 2025
Table 81. Thermo Fisher Scientific Sales Value Proportion by Application in 2025
Table 82. Thermo Fisher Scientific Sales Value Proportion by Geographic Area in 2025
Table 83. Thermo Fisher Scientific Pathological Tissue Microtome SWOT Analysis
Table 84. Thermo Fisher Scientific Recent Developments
Table 85. Medite Corporation Information
Table 86. Medite Description and Major Businesses
Table 87. Medite Product Models, Descriptions and Specifications
Table 88. Medite Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 89. Medite Sales Value Proportion by Product in 2025
Table 90. Medite Sales Value Proportion by Application in 2025
Table 91. Medite Sales Value Proportion by Geographic Area in 2025
Table 92. Medite Pathological Tissue Microtome SWOT Analysis
Table 93. Medite Recent Developments
Table 94. Slee Medical Corporation Information
Table 95. Slee Medical Description and Major Businesses
Table 96. Slee Medical Product Models, Descriptions and Specifications
Table 97. Slee Medical Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 98. Slee Medical Sales Value Proportion by Product in 2025
Table 99. Slee Medical Sales Value Proportion by Application in 2025
Table 100. Slee Medical Sales Value Proportion by Geographic Area in 2025
Table 101. Slee Medical Pathological Tissue Microtome SWOT Analysis
Table 102. Slee Medical Recent Developments
Table 103. RMC Boeckeler Corporation Information
Table 104. RMC Boeckeler Description and Major Businesses
Table 105. RMC Boeckeler Product Models, Descriptions and Specifications
Table 106. RMC Boeckeler Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. RMC Boeckeler Recent Developments
Table 108. MICROS Austria Corporation Information
Table 109. MICROS Austria Description and Major Businesses
Table 110. MICROS Austria Product Models, Descriptions and Specifications
Table 111. MICROS Austria Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. MICROS Austria Recent Developments
Table 113. AGD Biomedicals Corporation Information
Table 114. AGD Biomedicals Description and Major Businesses
Table 115. AGD Biomedicals Product Models, Descriptions and Specifications
Table 116. AGD Biomedicals Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. AGD Biomedicals Recent Developments
Table 118. Amos Scientific Corporation Information
Table 119. Amos Scientific Description and Major Businesses
Table 120. Amos Scientific Product Models, Descriptions and Specifications
Table 121. Amos Scientific Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. Amos Scientific Recent Developments
Table 123. Bright Instrument Corporation Information
Table 124. Bright Instrument Description and Major Businesses
Table 125. Bright Instrument Product Models, Descriptions and Specifications
Table 126. Bright Instrument Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. Bright Instrument Recent Developments
Table 128. Diapath Corporation Information
Table 129. Diapath Description and Major Businesses
Table 130. Diapath Product Models, Descriptions and Specifications
Table 131. Diapath Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 132. Diapath Recent Developments
Table 133. Histo-Line Laboratories Corporation Information
Table 134. Histo-Line Laboratories Description and Major Businesses
Table 135. Histo-Line Laboratories Product Models, Descriptions and Specifications
Table 136. Histo-Line Laboratories Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 137. Histo-Line Laboratories Recent Developments
Table 138. Auxilab Corporation Information
Table 139. Auxilab Description and Major Businesses
Table 140. Auxilab Product Models, Descriptions and Specifications
Table 141. Auxilab Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 142. Auxilab Recent Developments
Table 143. Nanolytik Corporation Information
Table 144. Nanolytik Description and Major Businesses
Table 145. Nanolytik Product Models, Descriptions and Specifications
Table 146. Nanolytik Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 147. Nanolytik Recent Developments
Table 148. Orion Medic Corporation Information
Table 149. Orion Medic Description and Major Businesses
Table 150. Orion Medic Product Models, Descriptions and Specifications
Table 151. Orion Medic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 152. Orion Medic Recent Developments
Table 153. S.M. Scientific Corporation Information
Table 154. S.M. Scientific Description and Major Businesses
Table 155. S.M. Scientific Product Models, Descriptions and Specifications
Table 156. S.M. Scientific Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 157. S.M. Scientific Recent Developments
Table 158. RWD Corporation Information
Table 159. RWD Description and Major Businesses
Table 160. RWD Product Models, Descriptions and Specifications
Table 161. RWD Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 162. RWD Recent Developments
Table 163. Dakewe Corporation Information
Table 164. Dakewe Description and Major Businesses
Table 165. Dakewe Product Models, Descriptions and Specifications
Table 166. Dakewe Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 167. Dakewe Recent Developments
Table 168. YIDI Medical Corporation Information
Table 169. YIDI Medical Description and Major Businesses
Table 170. YIDI Medical Product Models, Descriptions and Specifications
Table 171. YIDI Medical Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 172. YIDI Medical Recent Developments
Table 173. Key Raw Materials Distribution
Table 174. Raw Materials Key Suppliers
Table 175. Critical Raw Material Supplier Concentration (2025) & Risk Index
Table 176. Milestones in Production Technology Evolution
Table 177. Distributors List
Table 178. Market Trends and Market Evolution
Table 179. Market Drivers and Opportunities
Table 180. Market Challenges, Risks, and Restraints
Table 181. Research Programs/Design for This Report
Table 182. Key Data Information from Secondary Sources
Table 183. Key Data Information from Primary Sources

List of Figures
Figure 1. Pathological Tissue Microtome Product Picture
Figure 2. Global Pathological Tissue Microtome Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 3. Rotary Microtomes Product Picture
Figure 4. Cryostat Microtomes Product Picture
Figure 5. Sliding Microtomes Product Picture
Figure 6. Others Product Picture
Figure 7. Global Pathological Tissue Microtome Market Size Growth Rate by Level of Automation, 2021 vs 2025 vs 2032 (US$ Million)
Figure 8. Manual Microtome Product Picture
Figure 9. Semi-automated Microtome Product Picture
Figure 10. Fully Automated Microtome Product Picture
Figure 11. Global Pathological Tissue Microtome Market Size Growth Rate by Slice Thickness, 2021 vs 2025 vs 2032 (US$ Million)
Figure 12. 1–10 μm Product Picture
Figure 13. 0.1–1 μm Product Picture
Figure 14. 20–100 nm Product Picture
Figure 15. Global Pathological Tissue Microtome Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 16. Pathological Diagnosis
Figure 17. Pharmaceuticals
Figure 18. Scientific Research
Figure 19. Others
Figure 20. Pathological Tissue Microtome Report Years Considered
Figure 21. Global Pathological Tissue Microtome Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 22. Global Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 23. Global Pathological Tissue Microtome Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 24. Global Pathological Tissue Microtome Revenue-Based Market Share by Region (2021-2032)
Figure 25. Global Pathological Tissue Microtome Sales (Units), 2021-2032
Figure 26. Global Pathological Tissue Microtome Sales (CAGR) by Region: 2021 vs 2025 vs 2032 (Units)
Figure 27. Global Pathological Tissue Microtome Sales Market Share by Region (2021-2032)
Figure 28. Top 5 and Top 10 Manufacturers Pathological Tissue Microtome Sales Volume Market Share in 2025
Figure 29. Global Pathological Tissue Microtome Revenue-Based Market Share Ranking (2025)
Figure 30. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 31. Rotary Microtomes Revenue-Based Market Share by Manufacturer in 2025
Figure 32. Cryostat Microtomes Revenue-Based Market Share by Manufacturer in 2025
Figure 33. Sliding Microtomes Revenue-Based Market Share by Manufacturer in 2025
Figure 34. Others Revenue-Based Market Share by Manufacturer in 2025
Figure 35. Global Pathological Tissue Microtome Sales Volume-Based Market Share by Type (2021-2032)
Figure 36. Global Pathological Tissue Microtome Revenue-Based Market Share by Type (2021-2032)
Figure 37. Global Pathological Tissue Microtome ASP by Type (US$/Unit), 2021-2032
Figure 38. Global Pathological Tissue Microtome Sales Volume-Based Market Share by Level of Automation (2021-2032)
Figure 39. Global Pathological Tissue Microtome Revenue-Based Market Share by Level of Automation (2021-2032)
Figure 40. Global Pathological Tissue Microtome ASP by Level of Automation (US$/Unit), 2021-2032
Figure 41. Global Pathological Tissue Microtome Sales Volume-Based Market Share by Slice Thickness (2021-2032)
Figure 42. Global Pathological Tissue Microtome Revenue-Based Market Share by Slice Thickness (2021-2032)
Figure 43. Global Pathological Tissue Microtome ASP by Slice Thickness (US$/Unit), 2021-2032
Figure 44. Global Pathological Tissue Microtome Sales Market Share by Application (2021-2032)
Figure 45. Global Pathological Tissue Microtome Revenue-Based Market Share by Application (2021-2032)
Figure 46. Global Pathological Tissue Microtome ASP by Application (US$/Unit), 2021-2032
Figure 47. North America Pathological Tissue Microtome Sales YoY (Units), 2021-2032
Figure 48. North America Pathological Tissue Microtome Revenue YoY (US$ Million), 2021-2032
Figure 49. North America Top 5 Manufacturers Pathological Tissue Microtome Sales Revenue (US$ Million) in 2025
Figure 50. North America Pathological Tissue Microtome Sales Volume (Units) by Application (2021-2032)
Figure 51. North America Pathological Tissue Microtome Sales Revenue (US$ Million) by Application (2021-2032)
Figure 52. US Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 53. Canada Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 54. Mexico Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 55. Europe Pathological Tissue Microtome Sales YoY (Units), 2021-2032
Figure 56. Europe Pathological Tissue Microtome Revenue YoY (US$ Million), 2021-2032
Figure 57. Europe Top 5 Manufacturers Pathological Tissue Microtome Sales Revenue (US$ Million) in 2025
Figure 58. Europe Pathological Tissue Microtome Sales Volume (Units) by Application (2021-2032)
Figure 59. Europe Pathological Tissue Microtome Sales Revenue (US$ Million) by Application (2021-2032)
Figure 60. Germany Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 61. France Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 62. U.K. Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 63. Italy Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 64. Russia Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 65. Asia-Pacific Pathological Tissue Microtome Sales YoY (Units), 2021-2032
Figure 66. Asia-Pacific Pathological Tissue Microtome Revenue YoY (US$ Million), 2021-2032
Figure 67. Asia-Pacific Top 8 Manufacturers Pathological Tissue Microtome Sales Revenue (US$ Million) in 2025
Figure 68. Asia-Pacific Pathological Tissue Microtome Sales Volume (Units) by Application (2021-2032)
Figure 69. Asia-Pacific Pathological Tissue Microtome Sales Revenue (US$ Million) by Application (2021-2032)
Figure 70. Indonesia Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 71. Japan Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 72. South Korea Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 73. China Taiwan Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 74. India Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 75. Central and South America Pathological Tissue Microtome Sales YoY (Units), 2021-2032
Figure 76. Central and South America Pathological Tissue Microtome Revenue YoY (US$ Million), 2021-2032
Figure 77. Central and South America Top 5 Manufacturers Pathological Tissue Microtome Sales Revenue (US$ Million) in 2025
Figure 78. Central and South America Pathological Tissue Microtome Sales Volume (Units) by Application (2021-2032)
Figure 79. Central and South America Pathological Tissue Microtome Sales Revenue (US$ Million) by Application (2021-2032)
Figure 80. Brazil Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 81. Argentina Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 82. Middle East, and Africa Pathological Tissue Microtome Sales YoY (Units), 2021-2032
Figure 83. Middle East and Africa Pathological Tissue Microtome Revenue YoY (US$ Million), 2021-2032
Figure 84. Middle East and Africa Top 5 Manufacturers Pathological Tissue Microtome Sales Revenue (US$ Million) in 2025
Figure 85. Middle East and Africa Pathological Tissue Microtome Sales Volume (Units) by Application (2021-2032)
Figure 86. Middle East and Africa Pathological Tissue Microtome Sales Revenue (US$ Million) by Application (2021-2032)
Figure 87. GCC Countries Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 88. Turkey Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 89. Egypt Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 90. South Africa Pathological Tissue Microtome Revenue (US$ Million), 2021-2032
Figure 91. Pathological Tissue Microtome Industry Chain Mapping
Figure 92. Regional Pathological Tissue Microtome Manufacturing Base Distribution (%)
Figure 93. Global Pathological Tissue Microtome Production Market Share by Region (2021-2032)
Figure 94. Pathological Tissue Microtome Production Process
Figure 95. Regional Pathological Tissue Microtome Production Cost Structure
Figure 96. Channels of Distribution (Direct Vs Distribution)
Figure 97. Bottom-up and Top-down Approaches for This Report
Figure 98. Data Triangulation
Figure 99. Key Executives Interviewed

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療機器）の最新刊レポート

QYResearch社の 医療機器・消耗品分野 での最新刊レポート

本レポートと同じKEY WORD（tissue）の最新刊レポート


よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。


詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

当社ご利用のメリット
  1. ① お探しの情報に合わせてレポートをご紹介
  2. ② レポートで不足している情報はカスタマイズで対応可能
  3. ③ 特許情報、海外の法規制の取り組みなどディープな調査も対応可能
  4. ④ 円貨で請求書払い＆万全のアフターフォロー

 

2026/10/06　10:26

158.96 円

178.72 円

212.85 円

ページTOPに戻る

株式会社 データリソース　Data Resource, Inc.
東京都千代田区丸の内3-3-1 新東京ビル4F 430


A member of CORSS Business Producers Inc.
データリソースは2025年5月より
CROSS Business Producers株式会社 の100%子会社になりました。

電話：03-3582-2531
FAX：03-6551-2556
Eメール：office@dri.co.jp

会社概要 FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2025　DATA RESOURCE, Inc. ALL RIGHTS RESERVED.